Bring about a paradigm shift in the field of infectious diseases
AIS Biotech (where AIS stands for Anti Infective Sugar) is a French biotech company founded in March 2023 to develop a new class of sugar-based anti-infective biotherapies, designed to mimic the natural receptors of pathogens.
SUGAR-BASED BIOTHERAPIES AS A NEW CLASS OF ANTI-INFECTIVE AGENTS
AIS Biotech relies on a sustainable bioengineering platform to develop a pipeline of innovative sugar-based anti-infective agents that mimic the natural receptors of pathogens, helping to prevent viral resistance and minimize side effects.
Many viruses and bacteria bind to mammalian cells by recognizing specific oligosaccharide ligands. By mimicking cell receptors, glycomimetics can be used to prevent the binding of pathogens to host cell surface and neutralize the infection. AIS Biotech leverages a technological platform based on our UNIQUE know-how to produce, using a sustainable biotechnological process, custom oligosaccharides that mimic the natural pathogen’s receptors in order to neutralize or prevent infection.
Innovative sugar-based biotherapies
Based on 25 years of academic research, our biotechnological process has paved the way for a new class of anti-infective biotherapies
research
Preclinical development
bioprocess scale-up
Clinical proof of concept
AIS Biotech aims to develop a pipeline of alternate sugar-based therapies
Many pathogenic microorganisms utilize oligosaccharides as receptors to bind to the host cells. The strategy can be adapted to target many viruses and bacteria. Notable examples include MERS-CoV (the Middle East coronavirus which causes severe respiratory syndromes), as well as Avian and seasonal Influenza viruses, Parainfluenza viruses, Vibrio cholerae (which causes 100 000 deaths each year) noroviruses responsible for gastroenteritis outbreaks) and Helicobacter pylori (associated with stomach ulcers and cancers)…
glycoflu
Sustainability & Foundations
- Eco-friendly bioproduct
- Sugar-based biotherapy
- Bioproduction process
Innovative Science
- Antiviral activities
- Innovative MOA
- Validated PoC
- Proven Efficacy on A and B influenza viruses
Tackling Global Health Needs
- Public health concern
- Healthcare system burden
- Real unmet medical need
Safe & Patient-Centric Design
- Therapeutic and prophylactic uses
- No side effects
- Nasal administration
- Viral resistance bypass
AIS Biotech thrives on the skills and energy of an experienced and cohesive founding team to develop our game-changing anti-infective biotherapies
Aurélie juhem
CEO
Marion PASTOR
COO
jean-guillaume lafay
emeline richard millot
manuel rosa calatrava
We, in turn, are supported by an experienced strategic committee with expertise in biotech and pharmaceutical compagnies, as well as by a scientific advisory board composed of renowned experts in all key areas of our project.
AIS Biotech team attaches great importance to the impact of its activity
societal
Our mission is to combat infectious diseases and antimicrobial resistance by developing breakthrough therapies for unmet medical needs.
environmental
By preserving natural resources and developing greener products using bioproduction processes, AIS Biotech contributes to sustainable practices. Our technological platform allows us to move away from petrosourced chemistry.
Governance
Clear and transparent communication, integrity, collaboration, and ethical behavior in all actions and decisions, are core values of the company.
To develop its technology, AIS Biotech is supported by a strong and structured network of partners
AIS Biotech est co-financé par l’Union Européenne dans le cadre du Fonds Européen de Développement Régional (FEDER).